- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Gene Simmons, Chief Evangelist Officer at Invictus MD Strategies, Interviewed on BNN
Gene Simmons, Chief Evangelist Officer at Invictus MD Strategies, was recently interviewed by BNN’s Jon Erlichman.
Gene Simmons, Chief Evangelist Officer at Invictus MD Strategies, was recently interviewed by BNN’s Jon Erlichman. During the interview, Simmons discussed why he joined the Canadian cannabis company, highlighting the company’s management team, and the potential that he sees from the sale of cannabis.
“I’m fascinated by this company, Invictus, and I’m an investor,” said Simmons. “I have $10 million of stock in the company.”
He went on to say that he is ‘bullish’ about the company, notably impressed in how it is managed and how it does business.
Click here to connect with Invictus (TSXV:GENE, OTC:IVITF) for an Investor Presentation.
Source: www.bnn.ca
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.